Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study

Table 2

Subgroup analysis of length of stay in patients with primary discharge diagnosis of PE.

Characteristic	Warfarin plus enoxaparin; median LOS (days); (IQR)	Rivaroxaban; median LOS (days); (IQR)	LOS; value
Age (years)
≥60 (, 33)	4.5 (2.7, 5.9)	1.8 (1.2, 3.7)	<0.001
<60 (, 43)	4.0 (1.8, 5.9)	2.3 (1.6, 2.9)	<0.01
Classification
Stable (, 60)	4.0 (2.6, 5.8)	1.8 (1.3, 2.8)	<0.001
Submassive (, 14)	5.0 (2.7, 7.7)	3.6 (1.8, 4.2)	0.058
Payer type
Private (, 54)	3.7 (2.2, 5.8)	1.8 (1.5, 2.8)	0.002
Medicare/Medicaid (, 19)	4.1 (2.5, 6.1)	3.7 (1.8, 4.5)	0.093

= number in warfarin plus enoxaparin group and number in rivaroxaban group, respectively.
CrCl: creatinine clearance; IQR: interquartile range.
Massive PE not included due to low frequency of occurrences.